Direxion Daily S&P Biotech Bull 3X Shares (LABU)
ARCA ARCA Primary 
XMEX 
LABU Could Rip Higher if Biotech Finally Gets Its Long-Awaited Breakout
If you bought XBI a year ago and held it, you are up roughly 65%. If you bought Direxion Daily S&P Biotech Bull 3X Shares (NYSEARCA:LABU) on the same day, you are up about 235%.
Direxion Daily S&P Biotech Bull 3x Shares (NYSEARCA:LABU) Shares Gap Down – Here’s Why
Direxion Daily S&P Biotech Bull 3x Shares (NYSEARCA:LABU - Get Free Report) gapped down prior to trading on Friday. The stock had previously closed at $170.74, but opened at $164.08. Direxion Daily S&P Biotech Bull 3x Shares shares last traded at $165.2680, with a volume of 83,975 shares traded. Direxion Daily S&P Biotech Bull
Triple-Leveraged Biotech ETF Doubles as Regulatory Winds Shift in 2026
Triple-leveraged ETFs aren't for everyone, but if you believe biotech is about to break out, Direxion Daily S&P Biotech Bull 3X Shares (NASDAQ:LABU) offers the most aggressive way to capture that move.
New FDA Director Could Sway Biotech ETFs
Biotech stocks could sway toward the upside with the appointment of a new director at the Federal Drug Administration's Center for Drug Evaluation and Research. Dr. Richard Pazdur will take the reigns, bringing 26 years of related industry experience.
Buy LABU: Biotech Sector Benefits From Lower Interest Rates And AI
Seeking Alpha Quant rates LABU as a “HOLD”, but I rate it as a “BUY”. Markets expect the first interest rate cut at the September Fed meeting. LABU has strong momentum and benefits from lower interest rates.
